April, 2015 | Blue Horseshoe Stocks

Blue Horseshoe Stocks: PBR, INO, RAD Reviews & More

Petroleo Brasiliero, S.A. (Petrobras) PBR – Options

PBR has continued to perform this week after we caught it coming off its 52-week lows two Thursday’s ag o. At that time one of our main areas of interest was the 05/01 $6.50 Calls, which we subsequently observed trading at a low of .22. This week they’ve attained a high of .71, marking off a tidy 222% move.

The last time we touched upon PBR options on Monday morning, it was in the process of pushing even higher, so we suggested the possibility of rolling up our strike price to both the Weekly and May 1st $7 Calls, and that idea turned out to be a good one as well.

We’ve witnessed a trading range on the Weekly $7’s from .06 -.25, a whopping 316%, while the May 1st $7’s enjoyed an 87% run from .30 to .56.

Inovio Pharmaceuticals, Inc. INO

INO stands among those stocks that we have covered the most over the years. An INO tag search of our archives yields no less than 30 results. We re-flagged it in yesterday’s premarket report and the timing was quite fortuitous.

Yesterday morning the company had announced it had been selected as the leader of a $45M DARPA program to develop practical treatments for the Ebola virus. It fueled a continued rise off of recent lows, and this morning’s news could contribute to that as well. >> READ PR

INO heralded positive results from one of its studies, a DNA-based immunotherapy for the treatment of head and neck cancer. According to the CFO, the “initial data set from Inovio’s first cancer study provides encouraging evidence that we are on an important path to better optimized immunotherapy products.” >> READ PR

We’ll continue to keep watch over INO in the wake of these major developments.

Molycorp, Inc. MCP

MCP started showing up on our scanner back on March 23rd and 24th, when it was trading around .38. It retraced back to its 52-week low of .32 on the 27th.

After reappearing on our extended watchlist yesterday, it has traded as high as .62 in the premarket today; from a low of .484 that’s a 28% move up.

At .62, MCP had shown us a 94% overall move from its ultimate low set just the week before last. With gold and other precious metal prices on the rise again, we’ll continue to track MCP for more potential gain opportunities.

Rite-Aid Corp. RAD

We also wanted to make a quick mention of RAD. We tagged the stock for tracking back on December 4th and on that day we observed the lowest price the stock has traded at since then (5.48).

Since that time the stock has crept (and sometimes leaped) its way up the chart; it broke its 50DMA in early March, and managed break the $9-mark last Thursday, and then again yesterday. At Thursday’s high of 9.07, we had witnessed a total gain of 65%

Wall Street analysts are giving RAD high marks, and the stock is also receiving a 96% Overall “Buy” Rating at BARCHART.COM so we’ll certainly want to keep a close watch on RAD moving forward in the event that it sustains the bullish patterns it has been exhibiting over the past several months.

Extended Watchlist:
EXEL, OPXA, WPCS, MPET, MSTX, SLTD

Blue Horseshoe Stocks: VLTC, PZOO Updates & More

Pazoo, Inc. PZOO

A week ago today, we revisited PZOO in our morning report and were instantly rewarded for our good timing with a run from .0052 to .0071, a 37% intraday move. We let our readers know that we’d be monitoring the stock more closely moving forward, and this week it has once again begun an upswing.

After consolidating off of that initial pop, it ultimately found support at .0049 on Monday before turning northward once again and rebounding to .0068 (+39%).

It continued to set higher highs and higher lows during yesterday’s session as it traded in a range from .006-.008 (+33%), and finally cracked above its 50-day moving average, which was something we were looking to have happen.

To get an in-depth view of the current PZOO chart, click or tap on the graphic below:

Visit PZOO @ www.pazoo.com
The new site dedicated to its marijuana testing arm is located @ cannabisking.pazoo.com

Voltari Corp. VLTC

It was also last Wednesday that we alerted VLTC via our extended watchlist, and it didn’t take very long for this play to make a huge move.

VLTC touched a low of 2.18 on Thursday at the end of the short week, followed by a run to as high as 4.73 on Monday. That registered as a 117% session-over-session rip, and came on nearly seven times the 30-day average trading volume. A tip of the cap to anyone who took advantage of that rapid, hefty upswing!

Extended Watchlist:
TRBD, MCP, VRNG, INO, PSTR, DRYS

Blue Horseshoe Stocks: PMCB Special Report

PharmaCyte Biotech, Inc. PMCB

As we kick off the start of a new trading week, our point of focus is going to be PMCB, a clinical stage biopharma company. The Biopharma/Biotech sector has been enjoying a resurgence of late, evidenced by many such plays that we’ve already run across this year. What sets PMCB apart from the rest is the versatility of its flagship product, which we believe has significant disruptive potential in the marketplace upon further development.

The nature of PMCB‘s patented Cell-in-a-Box® technology lends to its high development potential, as it is a cellular treatment delivery method which could theoretically be utilized for virtually limitless applications. It can be generically referred to as a ‘cellulose-based live cell encapsulation technology’, but to explain exactly what that means to the average person requires a bit more detail.

Cellulose is an organic polymer which is the most abundant such compound in nature, being found in varying quantities in the cell walls of all plants. It is chemically inert, and its insolubility in the human body makes it an ideal carrier for potential treatments. Microscopic capsules constructed of cellulose are filled with living cells, either lab-engineered or cultured from natural compounds, and introduced into the body. The capsules have micropores which do not allow for the escape of the contained cells, but are sufficient in size to facilitate introduction of essential nutrients and beneficial substances produced by the cells. >> LEARN MORE

PMCB has several irons in the fire with Cell-in-a-Box®. It has been granted orphan-drug status by the FDA relating to the treatment of advanced pancreatic cancer, and the company currently has three separate Phase II trials underway testing its efficacy from multiple angles. >> LEARN MORE

In addition, the company has preclinical trials involving its technology’s implementation using cannabinoids, an active compound found in marijuana, which has the potential to help PMCB expand into another trendy sector. There are a number of other treatments in the preclinical phase, including those that treat diabetes, as well as brain and breast cancer.

Goldman Smallcap Research recently released a report on PMCB wherein senior analyst Rob Goldman referred to the company as a “prototypical acquisition target”. Based on what we ourselves have learned about PharmaCyte and the future potential of its many treatments, we’d find it hard to deny the possibility of PMCB getting picked up by a large pharmaceutical company at some point. >> GOLDMAN REPORT

FDA’s Record Approvals Bode Well for PharmaCyte’s Cancer Treatments (Tue 8:45AM EDT)
_____________________

CHART:

We can also see potential in the chart in the near-term. PMCB recently ran off of its 52-week low of .10, making a solid move to .16. Yesterday the stock began to consolidate off of that spike, and there could be a considerable bounce once the stock finds support. We’ll be looking for that to happen at or above the current 50DMA of .12. Beyond that, if PMCB can break resistance at .16, the next patch is sitting at the 200DMA, just shy of .20. The stock was trading at that level back in January, and a return there from current prices would leave us open to gains in the neighborhood of 40% or more.

We’ve also prepared a video presentation of the chart for your convenience:

Learn More About PMCB @ PharmacyteBiotech.com